The present invention provides a topical composition including a topical analgesic, a viscosity increasing agent, a humectant, an emollient, and an emulsifier. The topical composition is substantially free of volatile alcohol. Additionally, the present invention includes methods of relieving pain. The methods include topically applying to an exterior skin portion of the user's body in need of pain treatment a composition including a topical analgesic, a viscosity increasing agent, a humectant, an emollient, and an emulsifier.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
Provided are methods of treating skin using skincare compositions comprising (a) an emollient; (b) an occlusive; (c) a humectant; (d) a processed oat ingredient; (e) a rheological modifier; and (f) water.
Provided are skincare compositions comprising (a) an emollient; (b) an occlusive; (c) a humectant; (d) a processed oat ingredient; (e) a rheological modifier; and (f) water. Also provided are method of using and processing said compositions.
Provided are methods of quantifying miRNA in skin, the method comprising: applying a swellable microprotrusion array to a region of skin to absorb interstitial fluid; removing the microprotrusion array; recovering miRNA from the interstitial fluid absorbed into the microprotrusion array; and quantifying the miRNA. Also provided are methods of monitoring epigenetic changes in skin using a swellable microprotrusion array.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The present invention provides a sunscreen composition comprising: (a) diethylamino hydroxybenzoyl hexyl benzoate; (b) bis-ethylhexyloxyphenol methoxyphenyl triazine; (c) ethylhexyl triazone; and (d) methylene bis-benzotriazolyl tetramethylbutylphenol; wherein the sunscreen composition is substantially free of UV absorbers having a molecular mass of 380 Daltons or less.
The present invention provides a sunscreen composition comprising: (a) diethylamino hydroxybenzoyl hexyl benzoate; (b) bis-ethylhexyloxyphenol methoxyphenyl triazine; (c) ethylhexyl triazone; and (d) methylene bis-benzotriazolyl tetramethylbutylphenol; wherein the sunscreen composition is substantially free of UV absorbers having a molecular mass of 380 Daltons or less.
Sulfate-free cleansing compositions that include a surfactant and a conditioning agent are disclosed. The cleansing compositions are suitably thick and have a desired level of clarity. The cleansing compositions, which are slightly acidic, are mild to the skin and/or eyes.
The present invention relates to advanced methods of treating a wound comprising the steps of cleansing the wound with an antiseptic formulation, applying an antibiotic formulation to the wound, covering the wound with an adhesive bandage, and repeating these steps for at least two additional, consecutive days.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
The present invention provides an anhydrous sunscreen composition comprising: (a) at least about 15% by weight based on the total weight of the sunscreen composition of a combination of titanium dioxide and zinc oxide, wherein the weight ratio of zinc oxide to titanium dioxide in the composition is about 0.5 to about 1.5; (b) at least about 50% by weight based on the total weight of the sunscreen composition of a carrier oil, wherein the carrier oil comprises at least 50% by weight Helianthus Annuus (Sunflower) Seed Oil; (c) about 10% to about 20% by weight based on the total weight of the sunscreen composition a combination of Isododecane and Diisopropyl Adipate; and (d) about 2% to about 6% by weight based on the total weight of the sunscreen composition of a film former comprising triacontanyl PVP.
Methods of screening types and amounts of antioxidants, determining effectiveness of the antioxidants, preparing compositions including effective amounts of the antioxidants (and uses thereof), and reducing the formation of clogged pores and acne are provided. Methods include the formation of test samples in a solvent system (optionally with one or more bacterial metabolites) including one or more antioxidants in amounts to be evaluated for effectiveness against control samples without antioxidants. The samples are exposed to an oxidation-inducing element (such as UVA rays) and the amount of oxidation byproduct is evaluated. Based on the effectiveness of the antioxidant(s) in the amount(s) tested, formulations can be prepared to include the one or more antioxidants in the amount(s) effective to reduce oxidation of the oxidizable component, preventing and reducing the formation of the oxidation byproduct. The formulations can be used, for example, to reduce the formation of clogged pores and acne.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
A61K 9/00 - Medicinal preparations characterised by special physical form
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
15.
SYSTEM AND METHOD FOR SELECTIVE APPLICATION OF COSMETIC COMPOSITION TO IMPART UNDEREYE BRIGHTENING
A device and method for selectively applying a composition to a treatment surface (e.g., skin) to alter an aesthetic appearance of the skin in the undereye region of the face. The device includes an applicator applying the composition to the skin, and a detector obtaining image data corresponding to an image of an area of skin. The device generates a target reflectance value based on the image data and past image data. The target reflectance value is higher than reflectance of at least half of areas corresponding to the image data and past image data. The device determines a desired level of reflectance modification for a location within the area of skin imaged by comparing image data corresponding to reflectance of the location to the target reflectance value, and directs the applicator to selectively apply the composition to the location based on the desired level of reflectance modification.
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/09 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
Provided are methods of acclimating skin to a retinoid, the method comprising: topically applying to the skin a first composition comprising a retinoid at a first concentration at a first frequency for a first period of time; topically applying to the skin the first composition at a second frequency for a second period of time; topically applying to the skin a second composition comprising a retinoid at a second concentration at a third frequency for a third period of time; and topically applying to the skin the second composition at a fourth frequency for a fourth period of time.
Provided are compositions methods of preventing, delaying or ameliorating atopic dermatitis in a breastfed infant having an increased risk of developing an atopic disease, the method comprising administering a composition comprising administering a Bifidobacterium to the breastfed infant.
A system and method of determining an allergy impact profile of an individual are disclosed. The system and method may be employed to predict allergy impact environmental conditions may have on allergy symptoms of an individual and to recommend treatment of the individual in response to the predicted allergy impact.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G01D 21/00 - Measuring or testing not otherwise provided for
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
21.
METHOD TO MITIGATE ALLERGEN SYMPTOMS IN A PERSONALIZED AND HYPERLOCAL MANNER
A system and method of determining an allergy impact profile of an individual are disclosed. The system and method may be employed to predict allergy impact environmental conditions may have on allergy symptoms of an individual and to recommend treatment of the individual in response to the predicted allergy impact.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G01D 21/00 - Measuring or testing not otherwise provided for
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
22.
Systems and Methods for Automatic Cell Identification Using Images of Human Epithelial Tissue Structure
Systems and methods for improving the image quality of images of epithelial tissue structures are disclosed. The systems include training a first cycle-GAN model and a second cycle-GAN model simultaneously, where the first cycle-GAN model is trained to remove noise from an image and the second cycle-GAN model is trained to learn the structure of the image. Additional systems and methods include deploying the trained cycle-GAN model to identify an unknown image segment and/or generate a protocol for following the identified skin care treatment recommendation for an identified image segment.
Provided are methods and compositions suitable for treating acne, disrupting a biofilm, and/or killing bacteria contained in a biofilm. Certain methods comprise contacting skin in need of such treatment with a composition comprising two alpha hydroxy acids and a polyhydroxy acid.
Provided are methods and compositions suitable for treating acne, disrupting a biofilm, and/or killing bacteria contained in a biofilm. Certain methods comprise applying to a surface having a biofilm a composition comprising a first alpha hydroxy acid, a second alpha hydroxy acid, and a polyhydroxy acid.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Biomimetic, prebiotic, probiotic and postbiotic compositions and methods of use thereof are disclosed. The biomimetic, prebiotic, probiotic and postbiotic compositions may include bacteria of the genera Cutibacterium acnes (C. acnes), its culture and/or components thereof; and/or a substance that induces the growth or activity of C. acnes. The biomimetic, prebiotic, probiotic and postbiotic compositions may be used in preventing, improving and/or treating such conditions such as atopic dermatitis.
A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to a pharmaceutical liquid composition, wherein said liquid composition comprises at least one cooling agent comprising of a phenyl ring containing a polar side group at least one viscosity enhancing agent and at least one surfactant. The invention also relates to a method to produce such a pharmaceutical composition as well as a method of alleviating a symptom selected from the group consisting of cough, nasal congestion and sore throat in a subject comprising administering the composition according to any of preceding claims.
An absorbent article comprising a liquid permeable cover layer, an impervious barrier layer and an absorbent core between the cover layer and the barrier layer, wherein the barrier layer is impervious and biodegradable and comprises a kraft paper layer and a continuous resin coating; wherein the continuous resin coating is on the surface of the barrier layer disposed toward the absorbent core, and the continuous resin coating weight is from 10 to 18 g/m2, and the continuous resin coating is an acrylic copolymer.
A61F 13/514 - Backsheet, i.e. the impermeable cover or layer furthest from the skin
A61F 13/15 - Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
A61F 13/47 - Sanitary towels, incontinence pads or napkins
Provided are methods of reducing pain or itch, the method comprising administering to a patient in need thereof a therapeutically effective dose of a composition comprising a non-polar extract of Iceland moss.
Provided are methods of determining effectiveness of face treatments comprising: providing a front-facing image of the face prior to use of the treatment; identifying a y-axis of the face, wherein the y-axis is defined by a line connecting the center position of the chin of the face through the center of the face; identifying an x-axis of the face, wherein the x-axis is defined by a line that is positioned at a 90-degree angle from the y-axis and goes through the center of the chin of the face; selecting a facial landmark; identifying a facial landmark line, wherein the facial landmark line is defined by a line connecting the center position of the chin of the face to the facial landmark; measuring the angle between the x-axis and the facial landmark line; carrying out the treatment on the face; providing a front-facing image of the face after the treatment.
The present application describes methods of treating or reducing the onset or occurrence of childhood atopic disease. In particular, it relates to an integrated solution that accounts for temporal and sequential administrations of three different and specific approaches for optimal effectiveness in treating or reducing the onset or occurrence of childhood atopic disease.
The invention relates to a coated famotidine particle having at least a core and a coating layer, wherein the particle core comprises famotidine, a first filler and a first binder; and wherein the coating layer is substantially free from famotidine and comprises a second filler and a second binder. The invention also relates to solid dosage forms comprising said coated famotidine particle, and the use of the coated famotidine particle for treating a subject suffering from a disease or disorder in the gastrointestinal tract.
Systems, methods, and instrumentalities may be configured for managing infant health. An example system may communicate with a user device to collect and assess infant health metrics and parental usage. The system may configure a health trajectory for the infant by analyzing parental compliance and aggregate health data for generating an intervention data set. Interventions may be sent to the user device based on projected benefits and encouraging parental action. Health metrics may modify the health trajectory and interventions based on the infant's development and parental engagement. The system may monitor user compliance such that interventions are presented to maximize completion likelihood.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
42.
Systems, Methods, Mediums, and Apparatuses for Capturing Medications and Medication Usage
Systems, methods, non-transitory computer-readable mediums, and/or apparatuses are provided for determining a medication used by a patient. Label information for a medication may be determined. A source national drug code (NDC) associated with the medication may be determined. The source NDC may be validated. A product NDC and a normalized identifier may be determined. A brand name associated with the medication may be determined. One or more active ingredients associated with the brand name may be determined. A drug display name may be determined. The drug display name and active ingredient information for the one or more active ingredients may be displayed. A summary indicating an amount of the active ingredient may be displayed, for example, based on a medication diary.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 70/40 - ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
43.
TOPICAL COMPOSITIONS CONTAINING N-ACYL DIPEPTIDE DERIVATIVES AND GLYCOLIC ACID
The present invention provides topical compositions comprising a combination of an N-acyl dipeptide derivative and glycolic acid. The compositions provide enhanced penetration of the N-acyl dipeptide derivative into the skin.
Umbilical cord sensors for monitoring biomarkers and other information associated with an umbilical cord are provided. Some exemplary embodiments of sensors include both an outer body and expandable inner body, with both bodies being disposed at least partially around an umbilical cord, the inner body being disposed within the outer body. The expandable inner body defines a receiving channel for receiving the umbilical cord, and is selectively expanded and contracted to engage and disengage with the umbilical cord. One or more biosensors and/or one or more sampling features can be included as part of the umbilical cord sensors, with the biosensors measuring one or more parameters and the sampling features obtaining one or more biomarkers associated with the umbilical cord. Exemplary methods of using umbilical cord sensors during the childbirth process are also provided, among other sensor configurations and methods of use.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters
A61B 5/1464 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters specially adapted for foetal tissue
45.
METHODS AND COMPOSITIONS SUITABLE FOR THE TREATMENT OF ACNE
Provided are compositions suitable for treating acne, disrupting a biofilm, and/or killing bacteria contained in a biofilm. Certain compositions comprise
a. about 0.1 wt. % to about 7.5 wt. % glycolic acid;
b. about 0.1 wt. % to about 5 wt. % gluconolactone;
c. about 0.1 wt. % to about 5 wt. % mandelic acid
d. a glycol;
e. a salt-tolerant thickening polymer,
Provided are compositions suitable for treating acne, disrupting a biofilm, and/or killing bacteria contained in a biofilm. Certain compositions comprise
a. about 0.1 wt. % to about 7.5 wt. % glycolic acid;
b. about 0.1 wt. % to about 5 wt. % gluconolactone;
c. about 0.1 wt. % to about 5 wt. % mandelic acid
d. a glycol;
e. a salt-tolerant thickening polymer,
wherein the total amount of glycolic acid, gluconolactone and mandelic acid is less than about 15 wt. % of the total composition.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A tool that enables professional-level monitoring at home can provide patients with better access to expert advice regarding skin care. The tool may enable providing information about skin health to a patient's skin care specialist such that the most relevant information is emphasized and presented in a manner expected. The device may include a processor configured to receive a first skin image at a first time and a second skin image at a second time. The first and second time may be separated by a duration associated with a skin event. A plurality of skin characteristics may be determined from the first skin image and the second skin image. The processor may be configured to generate an analysis output and to transmit the analysis output to one or more receivers. The analysis output may include a synoptic representation of one or more of the plurality of skin characteristics.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
50.
Biomarkers Predictive of Atopic Dermatitis that Facilitate Prevention and/or Treatment of the Onset Atopic Dermatitis
A method to predict a propensity of an infant to develop atopic dermatitis. The method includes observing the expression of S100A8/A9 on a skin area of an infant; comparing the expression to determined standard, wherein the determined standard is ascertained by measuring a level of the biomarker in a subject or pool of subjects who have demonstrated an absence of atopic dermatitis; and determining the propensity of an infant to develop atopic dermatitis, wherein an increase in the expression as compared to the determined standard indicates propensity of the infant to develop atopic dermatitis.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Described are gummy dosage forms comprising tricalcium phosphate and a relaxing ingredient selected from Lemon balm extract, L-theanine, GABA, or mixtures thereof.
A container closure can include a collar, an actuator, and a biasing element. The collar can be configured to couple to a container. The collar can have a container facing surface and a second surface opposite the container facing surface. The actuator can be movable relative to the collar from a first position to a second position. The actuator can be in fluid communication with a cavity defined by the container such that the actuator dispenses material out of the container as the actuator moves from the first position to the second position. The biasing element can have a first portion coupled to the actuator and a second portion coupled to the second surface of the collar, the biasing element configured to bias the actuator toward the first position.
B05B 11/00 - Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
B05B 11/10 - Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle
The present invention is directed to an orally disintegrable multi-layered particle comprising a hydrophobic core containing simethicone, a hydrophilic surfactant layer, and a hydrophilic disintegrant layer; wherein said hydrophilic surfactant layer is located between the hydrophobic core and the hydrophilic disintegrant layer; and orally disintegrable solid dosage forms comprising said multi-layered particle, and related processes.
The present invention provides a sustainable shampoo that includes alapha-olefin sulfonate; betaine; sodium hydrolyzed potato starch dodecenylsuccinate; and water. The sustainable shampoo is in the form of a solid structure. The sustainable shampoo is gentle and non-irritating. Recyclable or biodegradable paper packaging can be used preferably to reduce energy consumption. The present invention also provides a method for preparing the sustainable shampoo.
An improved immediate release solid dosage form of naproxen with a certain particle size distribution for the intragranular portion, and a certain particle size distribution for the carbonate portion that allows naproxen to remain in solution and achieves fast dissolution and fast absorption of naproxen. The invention provides a naproxen dosage form that when administered to a human in a fasted state provides an average blood plasma naproxen concentration of at least 15-20 μg/ml in 10 minutes or less. The invention also provides a naproxen dosage form that when administered to a human in a fed state provides an average blood plasma naproxen concentration of at least 15-20 μg/ml in 50 minutes or less.
Provided are cleansing compositions comprising: (a) cocamidopropyl betaine, wherein the cocamidopropyl betaine has an average molecular weight of at least about 355 g/mol; (b) from greater than about 0 wt.-% to about 1 wt.-% of a fatty acid; and (c) water. Also provided are methods of using the same.
Provided are botanical or bacterial extracts and methods of treating skin and other tissues by applying certain botanical or bacterial extracts, such as from Acronychia acidula, Licaria vernicosa, Calendula officinalis, Trigonella foenum-graecum or Actimomyces bacteria, to the skin or other tissue.
A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
The present disclosure provides an oral cavity detection method. The method comprises: acquiring an ultraviolet light image of the oral cavity; determining a first region including a tooth region and at least one portion of a gum region based on the ultraviolet light image; acquiring a non-ultraviolet light image of the oral cavity; acquiring from the non-ultraviolet light image a first intermediate image that only includes the corresponding first region of the non-ultraviolet light image, based on the non-ultraviolet light image and the first region; determining a second region that only includes the tooth region, based on the first intermediate image; and determining the proportion of pixels containing dental plaque in a second intermediate image that only includes the corresponding second region of the ultraviolet light image. Through the combined use of ultraviolet light and non-ultraviolet light images, the oral cavity detection method proposed by one embodiment according to the present disclosure can accurately determine a tooth region, and thereby can accurately determine the proportion of pixels containing dental plaque, so as to provide a favorable basis for dental plaque assessment.
The present invention provides topical compositions comprising a combination ascorbic acid, caffeine, an inorganic salt, and water that are single aqueous phase compositions.
Provided in the present disclosure is an oral cavity examination method, including: acquiring an oral cavity image; performing median filtering and region segmentation operations on the image to obtain a first intermediate image; converting the first intermediate image from an RGB color space to an HSV color space to obtain a second intermediate image; determining a comparison threshold based on a tooth color; and determining a ratio of pixels within the comparison threshold to pixels of the second intermediate image based on the second intermediate image and the comparison threshold. The oral cavity examination method can set different comparison thresholds according to tooth colors of subjects, so as to perform targeted examination conforming to the characteristics of different subjects, making the ratio of the pixels within the comparison threshold to the pixels of the second intermediate image determined based on the second intermediate image and the comparison threshold more accurate and effective than the ratio determined by the conventional method, and thus facilitating subsequent evaluation of oral cavity health condition.
B65D 5/02 - Rigid or semi-rigid containers of polygonal cross-section, e.g. boxes, cartons or trays, formed by folding or erecting one or more blanks made of paper by folding or erecting a single blank to form a tubular body with or without subsequent folding operations, or the addition of separate elements, to close the ends of the body
85.
Window of Opportunity Skin Treatment Regimen and Composition for Preventing the Onset of or Treating Atopic Dermatitis
A device disclosed herein may be used for providing personal medical data. The device may comprise a memory and/or a processor. The processor may be configured to perform a number of actions. A graphic of a human body may be displayed. A user input associated with a location on the graphic of a human body may be received from a user. An organ context may be determined based on the location on the graphic of the human body. A biomarker related to the organ context may be determined. Contextualized health data that indicates a significance of the biomarker in relation to the organ context may be generated. In response to the user input, the device may display the contextualized health data, a recommended action, and an indication of an amount of time that the user's life may be extended by the user performing the recommended action.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A method to predict a propensity of an individual to develop atopic dermatitis is disclosed. The method, which involves use of biological markers, can also be used to evaluate the efficacy of a composition to treat atopic dermatitis.
An otoscope apparatus having an objective lens configured to focus light from an object, a field lens positioned parallel to the objective lens along an optical axis, a first aperture and a second aperture positioned, respectively, at a distal end and a proximal end of the objective lens, and a third aperture positioned at a distal end of the field lens. The otoscope apparatus is adapted to be releasably attached to a camera of a smart device. The otoscope apparatus may capture a picture or video of the outer ear, the middle ear, and/or the ear canal of a patient utilizing the camera of the smart device. Such a picture or video of the outer ear, the middle ear, and/or the ear canal may be sent to a remote healthcare professional for diagnosis of an ear infection.
A61B 1/227 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for ears, i.e. otoscopes
A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor with illuminating arrangements
A61B 1/05 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances characterised by the image sensor, e.g. camera, being in the distal end portion
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
Provided are compositions comprising an orally-acceptable carrier and an anionic copolymer derived from the polymerization of n-vinyl pyrrolidone (VP) with an anionic monomer compound containing phosphorus. Also provided are uses of such compounds in the oral cavity to inhibit demineralization of a tooth.
A61K 8/84 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions other than those involving only carbon-to-carbon unsaturated bonds
A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastes; Mouth rinses
A61K 8/92 - Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products
A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
Provided are compositions comprising an orally-acceptable carrier and a cationic copolymer derived from the polymerization of n-vinyl pyrrolidone (VP) with cationic monomers containing amines or by copolymerization of n-vinyl pyrrolidone (VP) monomers with cationic monomers comprising amides followed by deprotection to amines. Also provided are uses of such compounds in the oral cavity to inhibit demineralization of a tooth.
A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
A teething apparatus includes a water-resistant housing containing a controller and a power source and communication means and a plurality of sensors in communication with the surface of the housing arranged and configured to detect at least pH and at least one volatile organic compound. Each of the plurality of sensors is in data communication with the controller and the controller is capable of communication with an external device via communication means. The apparatus may be a component of a larger system and may be used in a method including the steps of providing a teething apparatus to an oral cavity of an infant, establishing a data connection between the teething apparatus and a remote device, and relaying information from the teething apparatus to the remote device, the information comprising the qualitative measurement of one or more volatile organic compounds and the quantitative value of pH in the oral cavity.
A novel device and method for delivering a liquid containing an active ingredient to a treatment site on the skin is disclosed. The device is useful for treating lesions or abnormal skin features such as corns, warts, calluses, bunions, actinic keratoses and hard hyperkeratotic skin as is often found on the face, arms, legs or feet.
A personal hygiene device may have a main body with an absorbent material configured to absorb a fluid, a sensor disposed within the main body, and a controller configured to communicate with the sensor. The sensor has a conductor and an insulator containing at least a portion of the conductor, and the sensor is configured to detect a first electrical value and a second electrical value that is different from the first electrical value. The sensor is also configured to transmit a signal to the controller upon detection of the second electrical value.
A61F 13/84 - Accessories, not otherwise provided for, for absorbent pads
A61F 13/42 - Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators with wetness indicator or alarm
A61F 13/472 - Sanitary towels, incontinence pads or napkins specially adapted for female use
A61F 13/49 - Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape specially adapted to be worn around the waist, e.g. diapers, nappies
A unit dose capsule for use with a sonic generator includes a deformable membrane adapted to releasably engage the distal end of the elongate horn, a nozzle including at least one delivery opening; a nozzle including at least one delivery opening; and a reservoir containing a liquid composition disposed therebetween. When the unit dose capsule is engaged to the distal end of the elongate horn, the nozzle is disposed in an outwardly facing orientation, and the reservoir is in liquid communication with the at least one nozzle. The unit dose capsule can be included in a kit with a handheld misting device comprising a housing having a dispensing window arranged and configured to contain a sonic generator and a power source.
B05B 17/06 - Apparatus for spraying or atomising liquids or other fluent materials, not covered by any other group of this subclass operating with special methods using ultrasonic vibrations
A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
An improved customizable dosage form comprising a substrate, such as a tablet core, that has one or more distinct, discreet cavities on its exterior surface, wherein simethicone is deposited into at least one of the cavities.
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
The present invention relates to curable compositions useful in the manufacture of absorbent films or absorbent film products. Methods of using and manufacturing the compositions also disclosed.
B01J 20/28 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
B01J 20/30 - Processes for preparing, regenerating or reactivating
99.
DEVICE FOR SUPPLYING A COMPOSITION TO A PRESSURIZED DEPOSITION SYSTEM
A device for dispensing a fluid topical composition includes a reservoir storing the composition and dispensing a pressurized flow of the composition. The device also includes an accumulator having an expandable chamber in fluidly communication with the reservoir. The chamber is biased towards a deflated configuration so that, when filled with the composition the chamber expands against this bias applying pressure to the composition stored therein. The device includes a supply valve regulating the flow of the composition from the reservoir to the accumulator, and a pressure sensor. The device further includes a processing arrangement analyzing data from the sensor to determine whether pressure in the accumulator is above a predetermined threshold and controlling the supply valve to maintain the pressure within a desired pressure range. The device also includes a deposition arrangement dispensing the composition from the accumulator under control of the processing arrangement.
B05B 9/08 - Apparatus to be carried on or by a person, e.g. of knapsack type
B05B 12/00 - Arrangements for controlling delivery; Arrangements for controlling the spray area
B05B 12/08 - Arrangements for controlling delivery; Arrangements for controlling the spray area responsive to condition of liquid or other fluent material discharged, of ambient medium or of target
A dosage form comprising a tablet core and one or more discontinuous coated regions in various configurations on the surface of the dosage form is disclosed. A method for making the dosage form is also disclosed.
B05C 1/02 - Apparatus in which liquid or other fluent material is applied to the surface of the work by contact with a member carrying the liquid or other fluent material, e.g. a porous member loaded with a liquid to be applied as a coating for applying liquid or other fluent material to separate articles
B05D 1/28 - Processes for applying liquids or other fluent materials performed by transfer from the surfaces of elements carrying the liquid or other fluent material, e.g. brushes, pads, rollers
A61K 9/00 - Medicinal preparations characterised by special physical form
B05D 1/40 - Distributing applied liquids or other fluent materials by members moving relatively to surface
B05C 13/02 - Means for manipulating or holding work, e.g. for separate articles for particular articles
B05D 5/06 - Processes for applying liquids or other fluent materials to surfaces to obtain special surface effects, finishes or structures to obtain multicolour or other optical effects
patents
